09:00 - 12:20
主持人 Moderator
- 于永明, 瀛玑智药（北京）科技有限公司总经理
- YU Yongming, General Manager, Yingji Zhiyao (Beijing) Technology Co., Ltd.
09:00 - 09:20
- 项目1
- Project 1
- 抗脑胶质瘤PDC药物LB001
- LB001, a Peptide-Drug Conjugate Targeting Glioma
- 张金华, 驯鹿生物创始人、董事长兼首席执行官
- ZHANG Jinhua, Founder, Chairwoman, and CEO of IASO Bio
09:20 - 09:40
- 项目2
- Project 2
- 南京滴力ADC项目介绍
- Nanjing Diligene Bio ADC Projects
- 刘军帅, 中国药促会政策专委会副主委
- LIU Junshuai, Vice-Chairman, PhIRDA Medicinal Policy Specialty Committee
09:40 - 10:00
- 项目3
- Project 3
- 针对IgE-FcεRI通路的阻断性抗体药物开发
- Development of Blocking Antibody Drugs Targeting the IgE-FcεRI Pathway
- 贺菊颖, 中信建投证券研究发展部联席负责人、未来产业和政策研究院执行院长
- HE Juying, Co-Head of Research & Development Department, China Securities Co., Ltd.; Executive Dean of the Institute for Future Industries and Policy
10:00 - 10:20
- 项目4
- Project 4
- 利用tBE技术开发创新型碱基编辑基因疗法
- Advancing Clinical Applications of Gene Editing Using Innovative Transformer Base Editor (tBE)
- 徐柏玲, 中国医学科学院药物研究所研究员
- XU Bailing, Professor, Institute of Materia Medica, Chinese Academy of Medical Sciences
10:20 - 10:40
- 项目5
- Project 5
- 科迈生物：基于生成式AI和多智能体协作的抗体从头设计平台
- Revolutionizing Antibody De Novo Designing Platform Based on Generative AI And Multi-Agent Collaboration
- 王校复, 太保健康研究院项目负责人
- WANG Xiaofu, Head of Health Research Institute Projects, China Pacific Insurance (Group) Co., Ltd.
10:40 - 11:00
- 项目6
- Project 6
- 基于类脑神经网络+AI在高效发现CNS候选药物中的应用和实践
- Brain-like Neural Networks (BNNs) + AI Enhance CNS Drug Discovery
- 金祺, 凯泰资本合伙人
- JIN Qi, Partner, Kaitai Capital
11:00 - 11:20
- 项目7
- Project 7
- 吸入靶向TSLP纳米抗体粉雾剂的研究与开发
- Development of an Inhaled TSLP-Targeting Nanobody Dry Powder Inhaler
- 杜向阳, 西南证券研究院副院长，医药生物行业首席分析师
- DU Xiangyang, Deputy Dean and Chief Healthcare Analyst of Southwest Securities Equity Research Department
11:20 - 11:40
- 项目8
- Project 8
- 新一代IG+抗体平台驱动的药物创新
- Next-generation IG+ Antibody Platform-driven Drug Innovation
- 袁清慧, 中信建投证券医药行业首席分析师
- YUAN Qinghui, Head of Healthcare Research at China Securities
11:40 - 12:00
- 项目9
- Project 9
- 现货型肿瘤原位治疗性疫苗
- Off-the-Shelf in Situ Therapeutic Vaccine for Tumors
- 李贵荣, 南京安懋华药业有限公司创始人/董事
- LI Guirong, Director of Nanjing Amazigh Pharma Ltd.
12:00 - 12:20
- 项目10
- Project 10
- 全球首个临床III期的HSV2溶瘤病毒最新进展
- The Latest Progress of the World's First Phase III Clinical HSV2 Oncolytic Virus
- 于海波, 中国医学科学院药物研究所教授
- YU Haibo, Professor, Institute of Materia Medica, Chinese Academy of Medical Sciences
会议咨询